Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti-PD-L1antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of humanIgG1antibody. Envafolimab blocks interaction betweenPD-L1andPD-1with anIC₅₀value of 5.25 nM. Envafolimab has the potential for the research of solid tumors^[1][2][3].

Envafolimab (0-2.51 nM) induces T-cell cytokine (IFN-γ) production in a dose- and time-dependent manner^[3].

Envafolimab (0.18-0.92 mg/kg; i.p.; four times over 2 weeks) shows antitumor activity with a half-life of ~72 h in NOD-SCID mice (A375 cells)^[3].

2102192-68-5

恩弗利单抗

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.